Camoxtin/Camoxtin ES Dosage/Direction for Use

Recommended Dose: Camoxtin: The usual recommended daily dosage is: 25/3.6 mg/kg/day in mild to moderate infections (upper respiratory tract infections e.g. recurrent tonsillitis, lower respiratory infections and skin and soft tissue infections).
45/6.4 mg/kg/day for the treatment of more serious infections (upper respiratory tract infections e.g. otitis media and sinusitis, lower respiratory tract infections e.g. bronchopneumonia and urinary tract infections).
The tables as follows give guidance for children. (See Table 1.)

Click on icon to see table/diagram/image

Children aged 2 months to 2 years: Children under 2 years should be dosed according to body weight. (See Table 2.)

Click on icon to see table/diagram/image

There is insufficient experience for dosage recommendations for children under 2 months old.
Camoxtin ES: Pediatric patients 3 months and older: The recommended dose for CAMOXTIN ES is 90/6.4 mg/kg/day in 2 divided doses at 12-hour intervals for 10 days. (See Table 3.)

Click on icon to see table/diagram/image

There is no experience in pediatric patients weighing >40 kg, or in adults.
There are no clinical data in children under 3 months of age.
CAMOXTIN ES does not contain the same amount of clavulanate as any of other CAMOXTIN suspension. Therefore, CAMOXTIN 457 should not be substituted for CAMOXTIN ES, as they are not interchangeable.
Renal impairment: Camoxtin: For children with GFR of >30 ml/min no adjustment in dosage is required.
Not recommended in children with GFR of <30 ml/min.
Camoxtin ES: Not recommended in children with renal impairment.
Infants with immature kidney function: Camoxtin: Not recommended in infants with immature kidney function.
Hepatic impairment: Use with caution. Use contraindicated in patients with a history of amoxicillin and clavulanic acid associated hepatic dysfunction.
Mode of Administration: Oral administration.
Administer at the start of meal to minimize potential gastrointestinal intolerance. The absorption is optimized when taken at the start of a meal.
Duration of the therapy should be appropriate to the indication and should not exceed 14 days without review.
Therapy can be started parenterally and continued with an oral preparation.
Instructions for Use/Handling: At time of dispensing, the dry powder should be reconstituted to form an oral suspension, as detailed as follows.
Check cap seal if intact before use.
Invert and shake bottle to loosen powder.
Fill the bottle with water to just below the mark on bottle label. Close the cap, invert and shake well, then top up with water to the mark. Close the cap, invert and shake again.
Allow to stand for 5 minutes to ensure full dispersion.
Shake well before taking each dose.